An MRI result with color gradations shows smaller metastases that current clinical scans might miss.
A new method to detect cancer in its early stages using a targeted MRI contrast agent that binds to proteins has been identified by a team of researchers led by Georgia State University Regents’ Professor Jenny Yang.
In their study, published in the journal Science Advances, Yang and her colleagues at Georgia State and Emory University describe a newly identified biomarker for detection of liver metastases. With current tests like biopsies, cancer in the liver is often detected in advanced stages, which can limit treatment options and lower overall survival rates. The discovery could have wide-ranging impacts, including more effective diagnosis and precision treatment, and less risk to patients.
“This is a game changer. It has the possibility to have many more applications, really for any type of cancer,” said Yang. “We are already applying it to 10 different types of cancer in the lab.”
The researchers, whose work is funded by the National Cancer Institute, developed an agent that can target certain receptors — in this case, chemokine receptor 4 (CXCR4). The receptor is overexpressed in common metastasis organs, such as the liver, among people who have cancer.
The CXCR4 targeted protein-based MRI contrast agent is expected to overcome major barriers in early diagnosis by showing even tiny instances of cancer cells on multi-color scans called precision MRI (pMRI), a new imaging methodology.
Using MRI technology, contrast agents carry the element gadolinium to enhance the images. During her previous work analyzing calcium, Yang decided to test how a metal, like gadolinium, would interact with protein. The protein wraps around the element and carries it to the site for imaging. Yang’s team found that protein design is much more effective in targeting the signs of disease.
“Currently, it is difficult to see early stages of disease in the liver, even in invasive biopsy,” said Yang. “Diagnostic testing using this contrast agent can not only identify the presence of disease but differentiate the stages of disease with high sensitivity and accuracy. That’s the beauty of this work.”
The findings are so promising, the targeted protein contrast agent is now being fast-tracked by the U.S. Food and Drug Administration (FDA) in the first step toward clinical trials to gauge its efficacy in humans.
“We have already met with the FDA, so we have a blueprint,” said Yang. “We hope within 18 months to two years we can conduct our first clinical trials in patents.”
Yang, who is also the associate director of the Center for Diagnostics and Therapeutics, holds 17 U.S. and 18 foreign patents in protein engineering. She recently became the university’s first professor to be awarded a fellowship by the National Academy of Inventors. Her start-up company InLighta Biosciences has been a key channel to allow her to compete for important funding and bring new discoveries to the marketplace.
The research builds on a 2019 study published in the journal Nature Communications, in which Yang’s team identified the first early detection of liver fibrosis using a collagen-targeted protein contrast agent. Combined, these studies represent the work of more than a dozen scientists from universities across the U.S., and their discoveries could help transform a $300 million industry that has seen few advances in the past several decades.
“We have been using the same contrast agents for 30 years with few breakthroughs,” said Yang. “I think this is my biggest scientific contribution. And I hope there are many more to come.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Detecting early-stage cancer
- Emirates Oncology Society and AstraZeneca partner to advance cancer screening and diagnosis in the UAEon August 9, 2020 at 1:32 am
The partnership aims to improve early detection of tumours and reduce cancer deaths in the UAE through an awareness programme, direct patient engagement and data management initiatives ...
- Cleveland Clinic joins study on blood test to detect 50+ cancerson August 6, 2020 at 1:05 pm
Cleveland Clinic will evaluate the use of a blood test that can detect more than 50 cancers as part of a multisite clinical trial, the system said Aug. 6. The blood test identifies DNA that cancerous ...
- Diagnostics Begin to Play a Greater Role in the Fight Against Canceron August 6, 2020 at 6:00 am
The diagnostics industry is highly diverse, with a vast number of testing methods already on the market and a consistent flow of ...
- UCLA Cancer Researchers Land $3 Million Granton August 4, 2020 at 5:00 pm
The purified liver cancer particles can then be subjected to molecular analysis, enabling noninvasive detection of early stage liver cancer from at-risk patients with cirrhosis of the liver.
- AnPac Bio Announces Preliminary Results From Prospective Trials Indicating Early-Stage Cancer Screening Effectivenesson August 4, 2020 at 4:43 am
AnPac Bio’s CDA technology has been demonstrated, in both retrospective and prospective studies, to be able to detect pre-cancer disease and early stage cancer signals with statistical significance.
Go deeper with Google Headlines on:
Detecting early-stage cancer
Go deeper with Bing News on:
- Even during a pandemic, prioritize lifesaving cancer screeningson August 9, 2020 at 7:00 am
It has been more than five months since Gov. Gary Herbert declared the initial state of emergency in Utah in response to the COVID-19 pandemic. Since then, each of us has experienced ...
- A Pakistani startup takes on early breast cancer detectionon August 8, 2020 at 7:31 pm
Our startup this week comes under exactly that. Meet Xylexa, an Islamabad-based startup that’s developing an artificial intelligence-powered, cloud-based tool to help in early cancer detection of ...
- American Cancer Society's new cervical cancer screening guidelines spark disagreement among physicianson August 7, 2020 at 1:19 pm
Some doctors are speaking out against the American Cancer Society's recently updated cervical cancer screening guidelines.
- Cleveland Clinic Joins Interventional Study Using GRAIL’s Multi-Cancer Early Detection Test to Help Guide Clinical Careon August 6, 2020 at 6:14 am
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, announced today that Cleveland Clinic has joined GRAIL’s PATHFINDER Study, a prospective, multi-center clinical study that is ...
- New Rapid Cardiac MR Imaging Helps Detect and Manage Patient Heart Health During and After Cancer Treatmentson August 5, 2020 at 9:00 am
United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, along with Myocardial Solutions, a medical technology company working to transform the cardiac and cancer care ...